Wed, November 30, 2011
[ Wed, Nov 30th 2011 ] - Market Wire
Watson Launches Generic LIPITOR
Tue, November 29, 2011
Mon, November 28, 2011
Sun, November 27, 2011
Fri, November 25, 2011
Thu, November 24, 2011
Wed, November 23, 2011
[ Wed, Nov 23rd 2011 ] - Market Wire
00 a.m. EST
Tue, November 22, 2011
[ Tue, Nov 22nd 2011 ] - Market Wire
BD Board Increases Dividend
Mon, November 21, 2011
Sun, November 20, 2011
Fri, November 18, 2011
Thu, November 17, 2011
Wed, November 16, 2011

Dendreon Announces Webcast Presentation at Upcoming Conferences


//health-fitness.news-articles.net/content/2011/ .. ebcast-presentation-at-upcoming-conferences.html
Published in Health and Fitness on Tuesday, November 22nd 2011 at 13:40 GMT by Market Wire   Print publication without navigation


SEATTLE--([ ])--Dendreon Corporation (Nasdaq:DNDN) today announced that management will present at the following conferences:

  • Deutsche Bank BioFEST in Boston, Massachusetts on December 5, 2011 at 9:30 am ET
  • NASDAQ OMX 27th Investor Program in London, UK on December 6, 2011 at 1:45 pm GMT

The presentations will be webcast live and available for replay from Dendreon's website, [ www.dendreon.com ]. If you are unable to listen to the live webcast, it will be archived on the site following the presentation. To access the replay, go to the Investor Relations section of the website.

About Dendreon

Dendreon Corporation is a biotechnology company whose mission is to target cancer and transform lives through the discovery, development, commercialization and manufacturing of novel therapeutics. The Company applies its expertise in antigen identification, engineering and cell processing to produce active cellular immunotherapy (ACI) product candidates designed to stimulate an immune response in a variety of tumor types. Dendreon's first product, PROVENGE (sipuleucel-T), was approved by the U.S. Food and Drug Administration (FDA) in April 2010. Dendreon is exploring the application of additional ACI product candidates and small molecules for the potential treatment of a variety of cancers. The Company is headquartered in Seattle, Washington and is traded on the NASDAQ Global Market under the symbol DNDN. For more information about the Company and its programs, visit [ http://www.dendreon.com/ ].


Publication Contributing Sources